AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05248347 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The BRONCH Mentor (Simbionix, GI-Bronch Mentor, USA)
Description: Participants who passed the theory test and was enrolled in this group will use this device to practice. After the appropriate time of practice, the test will be taken to evaluate the efficacy.
Study NCT06511765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine and dexamethasone injection solution
Description: Injection of Ropivacaine and dexamethasone
Study NCT06511765 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9% Injection Solution
Description: Injection of sodium chloride 0.9%
Study NCT06512792 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine management through Mobile APP
Description: According to the patient's electronic health records, each participating center researcher conducts personalized medication reminders and follow-up reminders for enrolled patients on a one-on-one basis. Simultaneously, patients are advised to monitor their health at home, regularly record and upload changes in clinical symptoms, medication, diet, exercise, etc., on the Mobile APP platform. Periodically, self-assessment scales are distributed through the Questionnaire Star platform to assess and record the patient's disease activity, quality of life, sleep, psychological status, etc., and update the information in the electronic health records.Based on the patient's clinical symptoms, self-assessment scales, and feedback from medical institution tests and examinations, each participating center researcher will promptly assess potential health risks, send warning alerts, and provide targeted informational support and interventions.
Study NCT06486714 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty
Description: All patients indicated for primary total knee arthroplasty will receive a cruciate-retaining cemented or cementless implant system, utilizing either MA or KA methodology.
Study NCT06486714 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty
Description: All patients indicated for primary total knee arthroplasty will receive a cruciate-retaining cemented or cementless implant system, utilizing either MA or KA methodology.
Study NCT05323708 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bmab 1000
Description: 60mg/ml Prefilled syringe single dose
Study NCT05323708 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolia®
Description: 60mg/ml Prefilled syringe single dose
Study NCT06335017 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Induction of labor
Description: In both groups the balloon catheter will be removed at nearly 12 hours after insertion. Following removal, artificial rupture of the membranes will be performed as long as it is safe with regards to fetal head position. Oxytocin infusion will be commenced at once if contraction has not begun spontaneously (2 to 3 regular uterine contractions per 10 minutes). Continuous electronic fetal monitoring will be used throughout labor. Labor will be managed by the attending obstetricians and midwives. Labor progress abnormalities will be diagnosed and managed according to the department protocol based on the recommendations of the American College of Obstetricians and Gynecologists.
Study NCT06583525 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Transition Support
Description: A multidisciplinary transition team (nurse practitioner and social worker) will coordinate the transition process for each patient across multiple settings, focused on the youth's highest priority needs while also supporting the caregivers. Participants will receive case management and care navigation using an intensive transition support model provided through the partnership of a transition team. The transition team will collaborate with the participants existing care team to help coordinate care, provide consultation, and support adult and primary care accepting these youth for 1 year following the transfer. This Intervention is modelled on best practices by Health Quality Ontario's Quality Standards for Transition from Youth to Adult Health Care Services to support youth at high risk of having poor transitional outcomes as they move from pediatric to adult care.
Study NCT05639530 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI333
Description: Intravitreal injection of IBI333
Study NCT06583707 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Dry needling with and without ultrasound guidance
Description: The dry needling technique involves inserting a sterile needle to stimulate a myofascial trigger point with the aim of reducing pain and increasing range of motion and quality of life. This technique can be performed using ultrasound guidance, which allows us to visualize the needle at all times, but it can also be done using anatomical landmarks. In the placebo dry needling technique, the needle will remain stationary in the subcutaneous tissue.
Study NCT06583707 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling with and without ultrasound guidance
Description: The dry needling technique involves inserting a sterile needle to stimulate a myofascial trigger point with the aim of reducing pain and increasing range of motion and quality of life. This technique can be performed using ultrasound guidance, which allows us to visualize the needle at all times, but it can also be done using anatomical landmarks. In the placebo dry needling technique, the needle will remain stationary in the subcutaneous tissue.
Study NCT06367283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be initiated at 500 mg once daily with breakfast meal. The dose will be increased with 500 mg every week until 2 g/day is reached, distributed as 1000 mg every morning and evening, together with a meal. If the subject cannot tolerate the maximum dose (2 g/day), the maximal tolerated dose will be given. The treatment period including titration is 16 weeks.
Study NCT06367283 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in the placebo group will receive a placebo tablet identical to the metformin tablet
Study NCT06233006 — intervention group
Intervention type: OTHER
Intervention: Assessment
Description: upper extremity functions (hand skills, hand and finger grip strength, reaction time, position sense, upper extremity strength and endurance) and health-related quality of life
Study NCT04885413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib in Combination With Anti-PD1 Antibody
Description: Sintilimab： 200mg i.v., d1, 21days one cycle Niraparib： 200mg p.o qd，d1-d21, 21days one cycle
Study NCT04803253 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ORTHOPUS prosthetic accessory: 0109 - Universal Wrist
Description: The ORTHOPUS mechanical wrist device is intended to provide an external wrist joint only for external upper limb prostheses with pronation/supination passive motion (activation with external force), a quick connection (with automatic lock) and manual disconnection of the mechanical wrist connectors.~The mechanical wrist connector allows to quickly switch between different type of terminal devices (hand or tools).
Study NCT04803253 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ORTHOPUS prosthetic terminal device: 0112 - Hook
Description: The ORTHOPUS body-powered hook is a Voluntary Opening (VO) device made of aluminium intended to provide high grasping capabilities under harsh environments.
Study NCT04803253 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ORTHOPUS prosthetic terminal device: 0105 - Cosmetic Articulated Hand
Description: The ORTHOPUS cosmetic articulated hand is intended to provide a replacement limb in order to hide the loss of the original one. It is composed of an aesthetic glove (18 colors and 3 sizes, silicone made) and of an internal structure that can be bent to achieve a given position allowing the user to grasp small and light objects.
Study NCT04803253 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ORTHOPUS prosthetic accessory: 0104 - body powered harness
Description: The ORTHOPUS body powered harness is intended to allow the patient to actuate the 0112 - Hook device. It will be installed on the patient's contralateral shoulder and linked to the 0112 - Hook device with a cable.
Study NCT04644692 — intervention group
Intervention type: OTHER
Intervention: Lung ultrasound
Description: A lung ultrasound before and at the end of the stress test.
Study NCT05190289 — intervention group
Intervention type: OTHER
Intervention: Pre-existing degenerative factors of paraspinal muscles and bone mass
Description: Pre-existing degenerative factors of paraspinal muscles, including muscle atrophy and fat infiltration; bone mass
Study NCT06471153 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowerment Program Based on BASNEF Model
Description: Initially, the researcher established rapport with children of both groups and their gradians, screened them for the eligibility criteria, explained the aim of the study, the duration and nature of the training sessions, and obtained informed assent. The researcher established the session objectives and learning activities and prepared the learning materials. The researchers also prepared the learning environment. The Empowerment program is implemented in accordance with the BANCEF model for behavior transformation into four educational sessions. After the intervention, children's nail-biting knowledge, practice, attitude, and self-efficacy were reassessed.
Study NCT06471153 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine Health Education
Description: Children in the control group received routine health education about the problems of nail-biting and routine advice to quit nail-biting.
Study NCT06133569 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ReDirection
Description: Self help program based on principles for cognitive behavioral therapy
Study NCT05026684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized cost handout
Description: Patients will be given a personalized cost handout to make transparent the full costs to Veterans of different types of ambulatory visits in order to optimize the value of their health care investments.
Study NCT05083312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APT-1011
Description: APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.
Study NCT05083312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo orally disintegrating tablet
Study NCT05472922 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placement of MiniMizer Gastric Ring
Description: Insertion of MiniMizer Gastric Ring in addition to the normal MGB-OAGB
Study NCT06602128 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Breathing Exercise Application Group
Description: The Effect of Breathing Exercise on Anxiety, Pain and Life Findings in Patients Undergoing Coronary Angiography
Study NCT05472922 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normal MGB-OAGB
Description: No insertion of Minimizer Gastric Ring in addition to the normal MGB-OAGB
Study NCT06606769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: supervised exercise training; twice a week for 12 months
Study NCT06721806 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRP & bone regeneration
Description: PRP effect on bone healing
Study NCT06721806 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PRP & bone regeneration
Description: PRP effect on bone healing
Study NCT06719557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1084
Description: Oral Tablet
Study NCT06719557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral solution
Study NCT06719557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin
Description: Oral capsule (extended)
Study NCT06496867 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Internal Fixation
Description: Early internal fixation of the LC1 fragility fracture of the pelvis will be defined as percutaneous anterior and/or posterior pelvic internal fixation with cannulated screw(s), medullary implant(s), or sacroiliac joint fusion device(s). The implant number, design, diameter, thread type (fully-threaded or partially-threaded), sacral segment (S1, S2, S3, or any combination there of), length, trajectory including sacroiliac or transsacral-transiliac, application with or without a washer, and ingrowth or ongrowth surface designs will be at the discretion of the treating surgeon.
Study NCT06496867 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nonoperative Care with Early Rehabilitation
Description: Nonoperative care with early rehabilitation will consist of nonoperative treatment of the pelvis fracture, including early consultation of the physical therapist, physiotherapist, or local equivalent rehabilitation provider at the time of randomization for a first attempt at mobilization of the patient within 24 hours of randomization. Patients who are unable to ambulate with assistance after five or more days of attempted mobilization by rehabilitation providers may be considered for delayed internal fixation treatment at the discretion of the patient and the treating surgeon. Delayed internal fixation after five or more days of attempted mobilization by rehabilitation providers will not be considered a treatment crossover event.
Study NCT04846543 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI Scan
Description: MRI scan
Study NCT05164614 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: RT-102 (80 μg)
Description: RaniPill capsule containing PTH with doses of 20 and 80 μg
Study NCT05164614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Forteo
Description: A commercial formulation of PTH for SC control (20 µg)
Study NCT05164614 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: RT-102 (20 μg)
Description: RaniPill capsule containing PTH with dose of 20μg
Study NCT02219373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Patients will be randomized to receive either Gabapentin or Oxcarbazepine. The assignment of the medications will be randomized and blinded to both the study investigators and the patient. If patients exhibit >30% pain reduction on receiving the medication evaluated after 4 weeks, then they may continue to receive either the same medication or placebo. If patients exhibit \<30% pain reduction, the patient will crossover to the other medication option in the protocol.
Study NCT02219373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gabapentin
Description: Patients will be randomized to receive either Gabapentin or Oxcarbazepine. The assignment of the medications will be randomized and blinded to both the study investigators and the patient. If patients exhibit >30% pain reduction on receiving the medication evaluated after 4 weeks, then they may continue to receive either the same medication or placebo. If patients exhibit \<30% pain reduction, the patient will crossover to the other medication option in the protocol.
Study NCT05747105 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Extension
Description: The 16-week protocol includes 11 total individual visits that integrate applicable elements of Cognitive Behavioral Therapy for Insomnia (CBT-I) and health behavior change theory. The first 6 weeks include weekly sessions (\~45 minutes each) focused on psychoeducation about sleep, goal-setting and self-monitoring, stimulus control, addressing cognitive and somatic arousal, sleep hygiene, and challenging negative thoughts about sleep. Sleep restriction will also be used in specific cases where sleep efficiency is low (\<85%). The remaining 10 weeks include briefer biweekly visits (5 visits, \~15-20 minutes each) to reinforce health behavior change strategies through topics such as problem-solving barriers, utilizing social support, identifying setbacks and creating an action plan, and relapse prevention. Self-reported sleep diary data and subjective sleepiness will be collected at each visit.
Study NCT05855603 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardioneuroablation
Description: Ganglionated plexi will be localized using an empirical anatomical approach and/or a fractionated electrogram-based strategy.~Point-by-point ablation will be performed using radiofrequency energy and an irrigated tip contact force sensing ablation catheter in a power control mode (35-50 W; AI, 350-500; LSI, 4.5-5.5). The right superior GP (RSGP), left superior GP (LSGP) and posterior left GP (PMLGP) will be targeted during CNA. Radiofrequency applications in other GPs will be left at the discretion of the operator.~At the end of the procedure, another EP study and atropine test will be performed. Clinical endpoints for completion of the CNA will be: 1) a HR increase >20% if the CNA was performed under general anesthesia/deep sedation; 2) improved electrophysiological parameters; 3) significant reduction in atropine response (HR increase \<10% after atropine); and 4) in case of using extracardiac vagal stimulation, lack of response.
Study NCT05855603 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Permanent pacemaker therapy
Description: All patients in the pacemaker group will receive a dual-chamber pacemaker that has the ability to be programmed in the DDD-CLS algorithm mode (or failing this, a dual-chamber pacemaker with RDR algorithm).
Study NCT02219373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Description: Patients will be randomized to receive either Gabapentin or Oxcarbazepine. The assignment of the medications will be randomized and blinded to both the study investigators and the patient. If patients exhibit >30% pain reduction on receiving the medication evaluated after 4 weeks, then they may continue to receive either the same medication or placebo. If patients exhibit \<30% pain reduction, the patient will crossover to the other medication option in the protocol.
Study NCT02219373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxcarbazepine
Description: Patients will be randomized to receive either Gabapentin or Oxcarbazepine. The assignment of the medications will be randomized and blinded to both the study investigators and the patient. If patients exhibit >30% pain reduction on receiving the medication evaluated after 4 weeks, then they may continue to receive either the same medication or placebo. If patients exhibit \<30% pain reduction, the patient will crossover to the other medication option in the protocol.
Study NCT02219373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients taking placebo will have placebo dose escalated using similar frequency, periods of time, and volumes as those for the active drugs.
Study NCT02219373 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients taking placebo will have placebo dose escalated using similar frequency, periods of time, and volumes as those for the active drugs.
Study NCT05004883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regulation of Cues Enhanced
Description: ROC is based on the Behavioral Susceptibility Theory and designed to incorporate psychoeducation, cue-exposure treatment, appetite awareness training, coping skills, and self-monitoring of satiety and cravings to treat high Food Responsiveness and low Satiety Responsiveness. BWL and ROC will be integrated for this arm, to capitalize on the strengths of both treatments. All participants will be taught to decrease caloric intake and increase physical activity, and to use all of the behavioral skills provided in BWL. However, they will also be taught models of hunger and satiety and about food cue reactivity, and will learn skills to manage these. This arm will include an experiential component, including hunger monitoring during dinner and participating in exposure exercises.
Study NCT05004883 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Weight Loss
Description: The BWL program includes dietary, physical activity, and behavioral change recommendations. All participants will be instructed on how to consume a balanced deficit diet of conventional foods; individual goals for energy intake will be based on initial body weight. Participants will be instructed in measuring portion sizes, counting calories, and self-monitoring food intake. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs. Behavior change recommendations include stimulus control, self-monitoring, goal setting, managing high-risk situations, meal planning, slowing eating, problem solving, social support, cognitive restructuring, lapse and relapse prevention skills, and maintaining weight loss.
Study NCT05004883 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Education, Stress Management and Social Support
Description: Topics included will be stress management/relaxation, social support, and nutrition education. There will be a strong mindfulness component to this group.
Study NCT05361915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abivertinib
Description: Abivertinib is a small molecule inhibitor
Study NCT05361915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Hormone-based chemotherapy
Study NCT04995601 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RF Health MAC
Description: The RF Health MAC is a novel device that is applied to the lower legs of patients that provides intermittent active compressions to the calf muscles which results in increased blood flow in the veins, moving blood towards the direction of the heart and reducing the risk of clot formation.
Study NCT05196074 — intervention group
Intervention type: OTHER
Intervention: Acute hypoxemic respiratory failure patients on VV-ECMO
Description: To describe the prevalence of complete airway closure in patients with acute hypoxemic respiratory failure on VV-ECMO and its association with outcome.